QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NYSEAMERICAN:VNRX

VolitionRx - VNRX Stock Forecast, Price & News

$1.68
-0.04 (-2.33%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.65
$1.74
50-Day Range
N/A
52-Week Range
$1.31
$3.30
Volume
70,486 shs
Average Volume
153,273 shs
Market Capitalization
$97.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67

VolitionRx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
237.3% Upside
$5.67 Price Target
Short Interest
Healthy
1.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$409,500 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars


VNRX stock logo

About VolitionRx (NYSEAMERICAN:VNRX) Stock

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Stock News Headlines

Maxim Group Sticks to Their Buy Rating for VolitionRX (VNRX)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Volition Issues Business Review 2022
Volition Announces Clinical Research Study with Oncovet
VolitionRX: Q2 Earnings Snapshot - Greenwich Time
See More Headlines
Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Company Calendar

Last Earnings
11/10/2021
Today
3/28/2023
Next Earnings (Estimated)
3/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:VNRX
Previous Symbol
NYSEMKT:VNRX
CIK
N/A
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.67
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+233.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-26,820,000.00
Net Margins
-15,452.74%
Pretax Margin
-15,607.46%

Debt

Sales & Book Value

Annual Sales
$90,000.00
Book Value
$0.33 per share

Miscellaneous

Free Float
48,838,000
Market Cap
$98.84 million
Optionable
Not Optionable
Beta
1.73

Key Executives

  • Cameron John Reynolds
    President, Chief Executive Officer & Director
  • Gaetan Michel
    Chief Operating Officer
  • Terig Hughes
    Chief Financial Officer & Treasurer
  • Jacob Vincent Micallef
    Chief Scientific Officer
  • Terry Kelly
    Chief Innovation Officer













VNRX Stock - Frequently Asked Questions

Should I buy or sell VolitionRx stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VNRX shares.
View VNRX analyst ratings
or view top-rated stocks.

What is VolitionRx's stock price forecast for 2023?

3 brokerages have issued 12-month price targets for VolitionRx's stock. Their VNRX share price forecasts range from $5.00 to $6.00. On average, they anticipate the company's stock price to reach $5.67 in the next year. This suggests a possible upside of 233.3% from the stock's current price.
View analysts price targets for VNRX
or view top-rated stocks among Wall Street analysts.

When is VolitionRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our VNRX earnings forecast
.

How were VolitionRx's earnings last quarter?

VolitionRx Limited (NYSEAMERICAN:VNRX) posted its quarterly earnings results on Wednesday, November, 10th. The medical research company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The medical research company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. VolitionRx had a negative net margin of 15,452.74% and a negative trailing twelve-month return on equity of 350.45%.

What other stocks do shareholders of VolitionRx own?
What is VolitionRx's stock symbol?

VolitionRx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

Who are VolitionRx's major shareholders?

VolitionRx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Lagoda Investment Management L.P. (6.55%), Morgan Stanley (0.44%), Cowen Prime Advisors LLC (0.31%), Spectrum Asset Management Inc. NB CA (0.10%), Cerity Partners LLC (0.07%) and Susquehanna International Group LLP (0.00%). Insiders that own company stock include Cameron John Reynolds, Guy Archibald Innes, Jacob Vincent Micallef, Jason Bradley Md Terrell, Kim Nguyen, Martin Charles Faulkes, Nicholas Plummer and Salvatore Thomas Butera.
View institutional ownership trends
.

How do I buy shares of VolitionRx?

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VolitionRx's stock price today?

One share of VNRX stock can currently be purchased for approximately $1.70.

How much money does VolitionRx make?

VolitionRx (NYSEAMERICAN:VNRX) has a market capitalization of $98.84 million and generates $90,000.00 in revenue each year. The medical research company earns $-26,820,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.

How can I contact VolitionRx?

VolitionRx's mailing address is 13215 BEE CAVE PARKWAY GALLERIA OAKS B SUITE 125, AUSTIN TX, 78738. The official website for the company is www.volitionrx.com. The medical research company can be reached via phone at (646) 650-1351, via email at investorrelations@volition.com, or via fax at 65 32 8172 5651.

This page (NYSEAMERICAN:VNRX) was last updated on 3/28/2023 by MarketBeat.com Staff